Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$10.16 - $13.11 $2.96 Million - $3.82 Million
-291,024 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$9.04 - $11.86 $501,783 - $658,313
-55,507 Reduced 16.02%
291,024 $3.25 Million
Q4 2020

Feb 02, 2021

SELL
$9.05 - $12.2 $140,944 - $190,002
-15,574 Reduced 4.3%
346,531 $3.95 Million
Q3 2020

Nov 05, 2020

BUY
$8.99 - $10.74 $81,809 - $97,734
9,100 Added 2.58%
362,105 $3.26 Million
Q2 2020

Aug 12, 2020

BUY
$9.14 - $11.97 $52,417 - $68,647
5,735 Added 1.65%
353,005 $3.64 Million
Q1 2020

May 12, 2020

BUY
$8.58 - $14.01 $235,692 - $384,854
27,470 Added 8.59%
347,270 $3.5 Million
Q4 2019

Jan 27, 2020

BUY
$8.22 - $14.0 $288,998 - $492,212
35,158 Added 12.35%
319,800 $4.26 Million
Q3 2019

Oct 31, 2019

BUY
$8.59 - $10.96 $468,464 - $597,714
54,536 Added 23.7%
284,642 $2.44 Million
Q2 2019

Aug 15, 2019

BUY
$9.8 - $12.89 $12,632 - $16,615
1,289 Added 0.56%
230,106 $2.52 Million
Q1 2019

May 03, 2019

SELL
$8.27 - $12.73 $166,301 - $255,987
-20,109 Reduced 8.08%
228,817 $3.1 Million
Q4 2018

Feb 08, 2019

SELL
$7.8 - $16.13 $130,283 - $269,419
-16,703 Reduced 6.29%
248,926 $2.58 Million
Q3 2018

Nov 13, 2018

BUY
$14.31 - $17.65 $641,145 - $790,790
44,804 Added 20.29%
265,629 $4.9 Million
Q2 2018

Aug 15, 2018

SELL
$11.83 - $16.2 $11,534 - $15,795
-975 Reduced 0.44%
220,825 $4.22 Million
Q1 2018

May 11, 2018

SELL
$11.13 - $13.63 $361,914 - $443,206
-32,517 Reduced 12.79%
221,800 $3.42 Million
Q4 2017

Feb 06, 2018

BUY
$12.16 - $14.58 $93,632 - $112,266
7,700 Added 3.12%
254,317 $3.81 Million
Q3 2017

Nov 15, 2017

BUY
$12.07 - $14.87 $2.98 Million - $3.67 Million
246,617
246,617 $3.89 Million

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $568M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track California Public Employees Retirement System Portfolio

Follow California Public Employees Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of California Public Employees Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on California Public Employees Retirement System with notifications on news.